DOCSLIB.ORG

Sign the Vienna Declaration

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sign the Vienna Declaration July 2010 The International AIDS Society (IAS) is the world’s leading independent association of HIV professionals. The IAS Newsletter is a tool for the organization’s diverse members to find out more about past, ongoing and future activities at the IAS and to learn how to become involved. For more information about the IAS, to search for and contact other members, or to find breaking news in HIV and AIDS prevention, care and treatment, and updates on upcoming IAS conferences, please visit the website at www.iasociety.org. Sign the Vienna Declaration Join the call of the international scientific community for drug A person previously addicted to drugs gives an educational lecture to patients at a drug policy reform. page 6 rehabilitation centre in Dhaka, Bangladesh. Photo: © G.M.B. Akash / Panos Pictures Message from the President page 2 AIDS 2010 to Intensify Focus on Introducing the New IAS Officers page 13 Message from the Acting Executive Director page 2 Human Rights page 5 The IAS Talks with Michel Kazatchkine page 14 Towards A Cure: IAS Pre-Conference The Vienna Declaration page 6 Regional Conferences Update page 15 Workshop page 3 IAS Activities at AIDS 2010 page 8 Measuring the Long-term Impact of the International Freedom and Equality in Africa page 4 Bridging the Divide: HIV and Health Systems page 11 AIDS Conference page 16 Universal Access Now Update page 12 2 Messages from the President and the Acting Executive Director IAS Newsletter July 2010 decreasing HIV transmission. This alone can addressing those needs requires that we have a “game-changing” effect on our work. change the course of global drug policy, em- bracing evidence over political expediency Yet, as evidence mounts and we are on the and criminalization. To that end, I urge you verge of even greater progress, we face an to read the Vienna Declaration on page 6 alarming retreat from political leaders on and visit www.viennadeclaration.com to sign their commitment to universal access. This on. The declaration will be one of the most cannot be allowed to stand. As those who important outcomes of AIDS 2010 and we know first-hand both the power and poten- need as many signatures as possible. Please tial of scaling up prevention and treatment sign it today. services to reach universal access, we must remain vocal advocates for the resources as i complete my tenure as IAS President, and political commitment necessary to I welcome my colleague Dr. Elly Katabira, achieve this goal. who will be the first African to hold this lead- Message from the ership position. Elly will bring tremendous With its Universal Access Now campaign, experience and a crucial perspective to his President the IAS is doing tremendous work to build presidency. I look forward to continuing to greater support for renewed commitments. work with him on the Governing Council. 2010 is a pivotal moment in our As we push for universal access, we must collective efforts to change the remain mindful of the need to embrace all it has been a tremendous honour to serve course of the HIV epidemic. those affected by HIV and AIDS, and, as we in this role, especially at this critical junc- prepare for Vienna, I am especially cognizant ture. It remains my deepest hope that our With four million people in low- and of the need for significant improvements in collective efforts to build a deep well of middle-income countries now on treatment, programmes for people who use drugs. As my scientific and programmatic evidence will we have conclusive evidence of our ability colleague Nora Volkow and I recently noted in move world leaders to action. to build large-scale, effective HIV treatment a JAMA editorial, “Ultimately, the HIV/AIDS programmes. At the same time, we have a epidemic cannot be adequately dealt with Julio Montaner critical new understanding of the secondary locally or internationally without addressing IAS President benefit of antiretroviral therapy (ART) on the needs of HIV-infected substance users.” With just months before the universal ac- i imagine that a great many of us will now cess deadline, AIDS 2010 could have been come to Vienna deeply frustrated by this the last checkpoint in reaching that goal and turn of events, and rightly so. While this commitment. is not where we would have hoped to find ourselves at this moment, we must act as donor nations should see and be wel- the circumstances demand. The fact that coming the tremendous return on their the G8 renewed its commitment to univer- investments – lives saved and productive sal access, but this time without a timeline work years extended. The most devastated and again without financial commitment, countries, now witnesses to the possibility does not help much. The crucial proof of of change, should be marshalling their own progress now depends on the success of the resources and increasing their resolve to be next Global Fund replenishment meeting true partners in HIV programme scale-up. just ahead of us. AIDS 2010 can be used to highlight what can be accomplished in the under this scenario, the impressive Universal next three years with the necessary influx Access Now campaign initiated by the IAS under of resources. the leadership of former Executive Director Robin Gorna would have never been necessary. as We continue making the case for uni- versal access, the call for human rights must Message from the Acting instead, We gather this July with the real- remain at the core. No matter how many Executive Director ity of more and more people living with HIV resources flow, our ultimate success is also that have been benefitting from the treat- dependent upon the expansion of human Since 2005 we have had a dream. ment scale-up now facing stock-outs while rights for those at risk for and living with others who envisioned starting treatment HIV. The opening of AIDS 2010 are rejected due to cruel financial pressures should have been a celebra- faced by funding agencies and implement- Mats Ahnlund tion of universal access to HIV ers on the ground. The notion that the Acting Executive Director prevention, treatment, care and world’s wealthy nations would make such significant investments in AIDS only to support. The dream included curtail those investments when momentum Editorial Committee: Shirin Heidari, Erika increased commitments from and science are on our side is unfathom- Lundstrom, Jacqueline Bataringaya, Scott donor and recipient nations able to those in need of treatment and those Sanders, Regina Aragón heartened by the impact of their who care for them. Equally disheartening Web Coordinator: Mona Dolan is the unwillingness of African nations to © International AIDS Society, Geneva Email: [email protected] ■ investments. fulfill their pledge to contribute 15% of their national budgets to health. IAS Newsletter July 2010 Towards a Cure: HIV Reservoirs and Strategies to Control Them 3 Towards a Cure: Current anti-HIV drugs do not eradicate HIV HIV Reservoirs and Strategies to Control START HAART STOP Them HIV infection is Antiretroviral drugs However, the virus characterized by high (HAART) are capable of rebounds after levels of circulating suppressing HIV, even to cessation of therapy. ias pre-conference Workshop: viruses in the blood. undetectable levels. 16–17 July 2010, vienna, austria By Alain Lafeuillade, Marie-Capucine Pénicaud VIRUS CIRCULATING Limit of detection and Sierra Milley-Boland “there is a strong need for continued TIME investments in basic research in order to HIV hides in reservoirs that are not sensitive to current therapies. increase our understanding of the mecha- Adapted from Nicolas Chomont, VTGI Florida nisms of HIV persistence and elaborate better and more affordable treatment op- The workshop organizers have placed a Session 5: What are Potential Therapeutic Interventions and How to Evaluate Them? tions,” noted Françoise Barré-Sinoussi, strong emphasis on ensuring representa- IAS Governing Council Member and tion of scientific excellence from around the Frank Maldarelli, National Cancer Institute, U.S. Chair of the pre-conference workshop in world, and scholarships will be provided for National Institutes of Health, will discuss what July 2009 at the 5th IAS Conference on HIV at least 62 participants. therapeutic strategies must be developed to Pathogenesis, Treatment and Prevention. target HIV reservoirs, and what tools are needed to assess their effect. Key issues reservoirs may hold Key to eradication The workshop programme will feature key- Closing Keynote Current antiretroviral drugs fail to com- note addresses delivered by some of the pletely eradicate the virus from the body world’s most distinguished researchers and Daria Hazuda, Merck Research Labs, will discuss because HIV rests in some cells in a numerous oral abstract presentations. the feasibility of HIV eradication. non-replicating stage called latent infec- tion. Over time, latent cells can become the programme Will cover a wide range next steps activated, causing HIV to begin replicat- of issues related to HIV reservoirs, from the In order to broaden the workshop’s impact, ing again. The strategies currently being characterization of viral reservoirs to the crucial the abstracts presented at the workshop and investigated to control HIV reservoirs may question of the feasibility of HIV eradication. an impact report will also be published in hold the key to the eradication of HIV. the Journal of the International AIDS Society. However, HIV eradication or even a ‘func- agenda For those interested in deepening their tional cure’ remain daunting challenges. knowledge of HIV reservoirs, The Fifth Opening Keynote International Workshop on HIV Persistence despite the availabilitY of new an- during Therapy will be held in St. Martin, tiretroviral drugs – easier to take and Steven Deeks, University of California, San West Indies, 6–9 December 2011.
Load more

Recommended publications
  • Presentation: IPPR Co-Chairs
    World Health Organization Executive Board Special Session October 6, 2020 Update from the Co-Chairs of The Independent Panel for Pandemic Preparedness and Response The Right Honourable Helen Clark, Co-Chair Her Excellency Ellen Johnson Sirleaf, Co-Chair Progress to Date – Key Milestones Resolution 73.1 WHO Director Secretariat Terms of Reference Executive Board adopted by World General appointed established. finalized. Special Session Health Assembly Co-Chairs for the Panelist Independent Panel nominations and Independent Panel for Pandemic comments on draft assembled and held st Preparedness & Terms of Reference. its 1 meeting. Response. Panelists selected May 2020 July 2020 August 2020 September 2020 October 2020 Terms of Reference • The Panel will review experience gained and lessons learned from the international health response to COVID-19 as coordinated by WHO and assess: • (i) the overall relevance and effectiveness of the international health response to the COVID-19 pandemic; WHO IHR Review • (ii) the functioning of the International Health Regulations (2005) and the status of Committee implementation of the relevant recommendations of previous IHR Review Committees; • (iii) the effectiveness of the mechanisms at WHO’s disposal and the actions of WHO and their timelines pertaining to the COVID-19 pandemic; • (iv) WHO’s contribution to United Nations-wide efforts. • In reviewing the experience gained and lessons learned from the WHO-coordinated international health response to COVID-19 as stated in the resolution the Panel will also: • (v) examine global health security threats and provide an analysis of past and future challenges and lessons learned; • (vi) include in its work analysis of the broader impacts of pandemics, including economic and social ones, and make recommendations to the extent that they have a direct bearing on future threats to global health security.
    [Show full text]
  • European Development Days
    2006 European Development Days 8 years of policy debates from the European Consensus to the post-2015 agenda /1 3 European Development Days 2006-2013 Eight years of policy debates from the European Consensus to the post-2015 agenda Europe Direct is a service to help you find answers to your questions about the European Union. Freephone number (*): 00 800 6 7 8 9 10 11 (*) Certain mobile telephone operators do not allow access to 00 800 numbers or these calls may be billed. More information on the European Union is available on the Internet (http://europa.eu). Luxembourg: Publications Office of the European Union, 2014 Paper version ISBN 978-92-79-38970-2 doi: 10.2841/47722 PDF ISBN 978-92-79-38969-6 doi: 10.2841/47692 © European Union, 2014 Reproduction is authorised provided the source is acknowledged. Printed in Belgium Printed on elemental chlorine-free bleached paper (ECF) European Development Days 2006-2013 Eight years of policy debates from the European Consensus to the post-2015 agenda Forward by José Manuel Barroso, President of the European Commission. This book has been published by the European Commission's Directorate-General for Development and Cooperation - EuropeAid in August 2014. European Commission FOREWORD by JOSÉ MANUEL BARROSO President of the European Commission I have always passionately believed in a Europe that I fought hard to preserve our high aid levels in our is open; a Europe that is committed to the values of multi-annual budget 2014-2020. In addition, my freedom, development and global solidarity. These Commission has stepped up special measures for the values have been central to the European project poorest, like the EUR 1 billion Food Facility or our ever since its inception and continue to inspire our strong support for the United Nation's Sustainable Union today.
    [Show full text]
  • A New Approach to Decriminalization
    New report from the Global Commission on Drug Policy ADVANCING DRUG POLICY REFORM: A NEW APPROACH TO DECRIMINALIZATION Commissioner Biographies Ruth Dreifuss Former President of Switzerland and Minister of Home Affairs Chair of the Global Commission on Drug Policy Ruth Dreifuss (born in 1940, single) studied in Geneva where she received a degree in economics with special focus on econometrics in 1971. In her varied professional career she served as hotel secretary, editor of the weekly journal Coopération, social worker, assistant at the Geneva University. She then worked nine years for the Swiss Agency for Development and Humanitarian Aid (Federal Department of Foreign Affairs) and became in 1981 Secretary of the Swiss Labour Union Federation. In that capacity, she was responsible for sectors including social insurance, labour law, gender equality and relations with the International Labour Organization (ILO). Ruth Dreifuss was elected Federal Councillor (Member of the Swiss government) in 1993 by the Federal Assembly (Parliament), and was re-elected twice. From 1993 to her resignation in 2002 she was Head of the Federal Department of Home Affairs, the ministry responsible for public health, social insurance, scientific research, higher education, gender equality and culture, so as environment until 1997. During the year 1999, Ruth Dreifuss was President of the Swiss Confederation. As responsible for public health and social insurance, she implemented a new policy in the fields of drug addiction and prevention of HIV/AIDS. She was also in charge with the introduction of the new law on health insurance, which guaranties a universal coverage for the Swiss population. After her retirement from government, she contributed to the WHO report on intellectual property rights, innovation and public health.
    [Show full text]
  • 1 Chris Beyrer, MD, MPH President-Elect, International AIDS
    Chris Beyrer, MD, MPH President-Elect, International AIDS Society Chris Beyrer MD, MPH, is Professor of epidemiology, International Health and Health, Behavior and Society at the Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland. He serves as Director of Johns Hopkins HIV Training Program in Epidemiology and Prevention Science, and founded and directs the university’s Center for Public Health and Human Rights. He is Co-Principal Investigator of the Johns Hopkins Center for AIDS Research (CFAR) and also serves as Associate Director of the Johns Hopkins Center for Global Health. He has extensive experience in conducting international collaborative research and training programs in HIV/AIDS and other infectious disease epidemiology, in infectious disease prevention research, HIV vaccine preparedness, in health and migration, and in health and human rights. Dr. Beyrer served as Field Director of the Thai PAVE and HIVNET studies from 1992-1996, based in Chiang Mai, northern Thailand, and has done extensive research in the epidemiology of HIV among key populations in Thailand, Burma, China, India, South Africa, Malawi, Tanzania, Russia, and Kazakhstan. He author of over 200 scientific papers, he has authored the 1998 book War in the Blood: Sex Politics and AIDS in Southeast Asia and co-edited the 2008 book Public Health and Human Rights: evidence-Based Approaches, and co-authored the 2011 book The Global epidemics of HIV among MSM in low and Middle Income Countries for the World Bank. 1 Professor Michel Kazatchkine, M.D. UN Secretary-General’s Special Envoy on HIV/AIDS in Eastern Europe and Central Asia Professor Michel Kazatchkine has spent the last 30 years fighting AIDS as a leading physician, researcher, administrator, advocate, policy maker, and diplomat.
    [Show full text]
  • The War on Drugs and HIV/AIDS How the Criminalization of Drug Use Fuels the Global Pandemic
    JUNE 2012 The War on Drugs and HIV/AIDS How the Criminalization of Drug Use Fuels the Global Pandemic REPORT OF THE GLOBAL COMMISSION ON DRUG POLICY Upper Left: Protesters at London’s Russian Embassy demand the introduction of opiate substitution therapy and the scale-up of syringe access programs. Photo: International Network of People who Use Drugs www.inpud.net SECRETARIAT ADVISORS FOR ADDITIONAL RESOURCES, SEE: Ilona Szabó de Carvalho Dr. Alex Wodak, Australian www.unodc.org Miguel Darcy de Oliveira Drug Law Reform Foundation www.drugpolicy.org Patricia Kundrat www.adlrf.org.au www.icsdp.org Rebeca Lerer www.idpc.net Ethan Nadelmann, www.igarape.org.br Drug Policy Alliance SUPPORT www.talkingdrugs.org www.drugpolicy.org Igarapé Institute www.tni.org/drugs Dan Werb, International Centre for www.ihra.net Instituto Fernando Science in Drug Policy www.countthecosts.org Henrique Cardoso www.icsdp.org www.intercambios.org.ar Open Society Foundations www.cupihd.org Dr. Evan Wood, International www.wola.org/program/drug_policy Sir Richard Branson, founder and Centre for Science in Drug Policy www.beckleyfoundation.org chairman of Virgin Group (Support www.icsdp.org www.comunidadesegura.org provided through Virgin Unite) Martin Jelsma, Transnational Institute www.tni.org/drugs Mike Trace, International Drug Policy Consortium www.idpc.net REPORT OF THE COMMISSIONERS GLOBAL COMMISSION Aleksander Kwasniewski, former President of Poland ON DRUG POLICY Asma Jahangir, Human rights activist, former UN Special Rapporteur on Arbitrary, Extrajudicial and Summary Executions, Pakistan Carlos Fuentes, Writer and public intellectual, Mexico – in memoriam César Gaviria, former President of Colombia Ernesto Zedillo, former President of Mexico Fernando Henrique Cardoso, former President of Brazil (Chair) George Papandreou, former Prime Minister of Greece George P.
    [Show full text]
  • Second Report on Progress
    Second report on progress Prepared by the Independent Panel for Pandemic Preparedness and Response for the WHO Executive Board, January 2021 This is the second report on progress from the Independent Panel for Pandemic Preparedness and Response. The report represents over three months of work by the full Panel since it held its first meeting on 17 September 2020. This report has been informed by the review of hundreds of documents, expert consultations across many sectors, case studies, submissions received by the Panel from Member States, academia, civil society , and citizens, and almost 100 interviews with those at the frontlines of pandemic preparedness and response. The work of the Panel, however, is not yet complete and, as detailed in this report, there are a number of critical questions which remain to be examined in depth before conclusions can be drawn and recommendations made. The first progress report was presented to the resumed session of the 73rd World Health Assembly on 5 November 2020. Following this report, the Panel will again report to the 74th World Health Assembly scheduled for May 2021. Disclaimer: The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Independent Panel for Pandemic Preparedness and Response concerning the legal status of any country, territory, city of area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Table of Contents Preface 4 Key messages 5 Progress, observations and next steps 9 1. Build on the past 10 Conditions around the emergence of the pandemic 10 Preparedness assessment and previous panels 12 2.
    [Show full text]
  • Thursday, 14 May 2020 Uniting Behind a People's Vaccine Against
    Thursday, 14 May 2020 Uniting Behind A People’s Vaccine Against COVID-19 Humanity today, in all its fragility, is searching for an effective and safe vaccine against COVID-19. It is our best hope of putting a stop to this painful global pandemic. We are calling on Health Ministers at the World Health Assembly to rally behind a people’s vaccine against this disease urgently. Governments and international partners must unite around a global guarantee which ensures that, when a safe and effective vaccine is developed, it is produced rapidly at scale and made available for all people, in all countries, free of charge. The same applies for all treatments, diagnostics, and other technologies for COVID-19. We recognize that many countries and international organizations are making progress towards this goal, cooperating multilaterally on research and development, funding and access, including the welcome $8 billion pledged on 4th May. Thanks to tireless public and private sector efforts and billions of dollars of publicly-financed research, many vaccine candidates are proceeding with unprecedented speed and several have begun clinical trials. Our world will only be safer once everyone can benefit from the science and access a vaccine - and that is a political challenge. The World Health Assembly must forge a global agreement that ensures rapid universal access to quality-assured vaccines and treatments with need prioritized above the ability to pay. It is time for Health Ministers to renew the commitments made at the founding of the World Health Organization, where all states agreed to deliver the “the highest attainable standard of health as a fundamental right of every human being”.
    [Show full text]
  • From Evidence to Action: to Evidence from International Harm Reductioninternational Association of the International Harm Reduction Association
    International Harm Reduction Association About the International Harm Reduction Association and HR2 The International Harm Reduction Association (IHRA) is one of the leading international non-governmental organisations promoting policies and practices that reduce the harms from all psychoactive substances, harms which include not only the increased vulnerability to HIV and hepatitis C infection among people who use drugs, but also the negative social, health, economic and criminal impacts of illicit drugs, alcohol and tobacco on individuals, communities and society. A key principle of IHRA’s approach is to support the engagement of people and communities affected by drugs and alcohol around the world in policy-making processes, including the voices and perspectives of people who use illicit drugs. In 2007, IHRA established HR2, the Harm Reduction & Human Rights Programme. HR2 leads the organisation’s programme of research and advocacy on the development of harm reduction programmes and human rights protections for people who use drugs in all regions of the world. IHRA is an NGO in Special Consultative Status with the Economic and Social Council of the United Nations. About the Authors Michel D Kazatchkine is the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria. He spent the past 25 years fighting AIDS as a leading physician, researcher, administrator, advocate, policy maker and diplomat. Before joining the Fund, besides being Professor of Immunology at University Paris Descartes and Head of the Immunology Unit of the Georges Pompidou Hospital in Paris, he played key roles in various organisations, serving as Director of the Agence Nationale de Recherche sur le Sida et le hépatites (ANRS) (1998-2005) in France, Chair of the WHO’s Scientific and Technical Advisory Committee (STAC) on HIV/AIDS (2004-2007), member of the WHO’s STAC on TB (2004-2007), and French Ambassador on HIV/AIDS and communicable diseases (2005- 2007).
    [Show full text]
  • LETTRE OUVERTE LETTRE OUVERTE : S’Unir Pour Un Vaccin Pour Tou-Te-S Contre Le COVID-19
    2020-05-14T13:23:58.730Z Oxfam International LETTRE OUVERTE LETTRE OUVERTE : S’unir pour un vaccin pour tou-te-s contre le COVID-19 Oxfam International Follow May 14 · 11 min read L’humanité d’aujourd’hui, vulnérable face à ce virus, est à la recherche d’un vaccin eõcace et sûr contre le COVID-19. C’est notre meilleur espoir de mettre un terme à cette douloureuse pandémie mondiale. Nous demandons aux ministres de la santé réunis à l’Assemblée mondiale de la santé de se rallier d’urgence à la cause d’un vaccin pour tou-te-s contre cette maladie. Les gouvernements et les partenaires internationaux doivent s’engager : lorsqu’un vaccin sûr et eõcace sera développé, il devra être produit rapidement à grande échelle et mis gratuitement à la disposition de tous, dans tous les pays. Il en va de même pour tous les traitements, diagnostics et autres technologies contre le COVID-19. Nous reconnaissons que de nombreux pays et organisations internationales progressent vers cet objectif, en coopérant multilatéralement en matière de recherche et de développement, de ùnancement et d’accès, y compris les 7,4 milliards d’euros annoncés le secteurs public et privés, et à des milliards de dollars de recherche ùnancée par les pouvoirs publics, la découverte d’un vaccin potentiel progresse à une vitesse sans précédent et plusieurs essais cliniques ont déjà commencé. Notre monde sera plus sûr que lorsque tout le monde pourra bénéùcier de la science et avoir accès à un vaccin — ce qui est un déù politique. L’Assemblée mondiale de la santé doit parvenir à un accord mondial qui garantisse un accès universel rapide à des vaccins et à des traitements de qualité, les besoins étant prioritaires sur la capacité de payer.
    [Show full text]
  • A Guide to Global Health Diplomacy
    A GUIDE TO GLOBAL HEALTH DIPLOMACY SPEAKERS OPENING REMARKS: TEDROS ADHANOM GHEBREYESUS Director General, WHO Dr Tedros Adhanom Ghebreyesus was elected as WHO Director-General for a five-year term by WHO Member States at the Seventieth World Health Assembly in May 2017. He is the first WHO Director-General to have been elected from multiple candidates by the World Health Assembly, and is the first person from the WHO African Region to serve as WHO’s chief technical and administrative officer. Immediately after taking office on 1 July 2017 Dr Tedros outlined five key priorities for the organisation: universal health coverage; health emergencies; women’s, children’s and adolescents’ health; health impacts of climate and environmental change; and a transformed WHO. Prior to his election as WHO Director- General, Dr Tedros served as Ethiopia’s Minister of Foreign Affairs from 2012–2016. In this role he led efforts to negotiate the Addis Ababa Action Agenda, in which 193 countries committed to the financing necessary to achieve the Sustainable Development Goals. Dr Tedros served as Ethiopia’s Minister of Health from 2005–2012, where he led a comprehensive reform of the country’s health system. All roads lead to universal health coverage for Dr Tedros, and he has demonstrated what it takes to expand access to health care with limited resources. The transformation he led as Ethiopia’s Minister of Health improved access to health care for millions of people. Under his leadership Ethiopia invested in critical health infrastructure, expanded its health workforce, and developed innovative health financing mechanisms. Beyond Ethiopia, Dr Tedros’ global leadership on malaria, HIV/AIDS, and maternal and child health has been immensely impactful.
    [Show full text]
  • Independent Panel 5Th Meeting Report
    Photo: Esther Ruth Mbabazi Meeting Report Fifth Meeting of the Panel 17 – 18 March 2021 Report Summary The Independent Panel for Pandemic Preparedness and Response met virtually for its fifth meeting on the 17 and 18 March 2021. Opening the meeting, Co-Chair Her Excellency Ellen Johnson Sirleaf noted that the Panel’s fact-finding and analyses were largely complete. She noted that people who are poor, people who are marginalized, and those who have faced structural injustices are at a disadvantage before, during, and after the pandemic, and that the Panel must keep their lives and their voices at the fore when considering its conclusions and recommendations. The Rt Hon Helen Clark noted that the time had come to move forward from fact-findings to draw conclusions and consider recommendations. The Panel received an analysis of a 28-country in depth review of national responses, and also updated data on the socio-economic impact of the pandemic. Key differences were observed between high and low performing countries in their strategies, and which interventions were deployed in responding to the COVID-19 pandemic. These were shaped by a range of contextual factors from prior experiences to civil service capabilities, with successful responses observed in centralised and decentralised systems. The Panel considered what recommendations for a system reset could be. There was agreement that recommendations should be bold, with the aim of preventing future disease outbreaks evolving into pandemics. The meeting concluded with a presentation of the outline of the final Panel report and outreach and communication strategies. Panel members are committed to work up to and beyond the report launch to ensure that the recommendations are taken up by relevant stakeholders and can catalyse necessary transformative change.
    [Show full text]
  • GFO), an Independent Newsletter About the Global Fund Provided by Aidspan to Over 10,000 Subscribers
    GLOBAL FUND OBSERVER (GFO), an independent newsletter about the Global Fund provided by Aidspan to over 10,000 subscribers. Issue 71 – 8 February 2007. (For formatted web, Word and PDF versions of this and other issues, see www.aidspan.org/gfo ) + + + + + + + + + + + + + + + + + + + CONTENTS + + + + + + + + + + + + + + + + + + + 1. NEWS: Board Chooses Michel Kazatchkine to be Global Fund’s Next Executive Director The Board has chosen Dr. Michel Kazatchkine, a leading expert on HIV/AIDS, to serve as the next Executive Director of the Global Fund. A French citizen, he served in earlier years as the first Chair of the Fund’s Technical Review Panel and as Vice-Chair of the Board. He replaces Richard Feachem, the first Executive Director, who steps down on March 31 after nearly five years’ service. 2. BIOGRAPHY: Michel Kazatchkine Michel Kazatchkine has spent the past twenty years fighting AIDS as a leading physician, researcher, administrator, advocate, policymaker and diplomat. + + + + + + + + + + + + + + + + + + + 1. NEWS: Board Chooses Michel Kazatchkine to be Global Fund’s Next Executive Director + + + + + + + + + + + + + + + + + + + The Global Fund today issued the following press release: 8 February 2007 Professor Michel Kazatchkine Selected as Executive Director of the Global Fund Geneva – The Board of the Global Fund has chosen Michel Kazatchkine, a physician and global health expert, as the next Executive Director of the Global Fund. He replaces Sir Richard Feachem, the founding Executive Director, who steps down at the end of his five-year term on March 31. Professor Kazatchkine is a physician who has treated people with AIDS for more than 20 years and led the world’s second-largest AIDS research agency.
    [Show full text]